BackgroundSince more than two decades Risk-reducing salpingo-oophorectomy (RRSO) is recommended and widely accepted by BRCA1/2 carriers as a method reducing ovarian cancer risk and improving survival rate. After RRSO, there remains a risk of breast cancer and peritoneal cancer. The characteristics of these neoplasms are not well known. In this study, we determined the selected parameters such as age at cancer diagnosis, time from RRSO to the diagnosis of cancer, and significance of BRCA1 mutation type in patients diagnosed with breast or peritoneal cancer during postoperative follow-up.MethodsThe material comprised of 195 BRCA1 carriers who performed RRSO between years 1999–2012. In this period, 16 patients developed cancer (6-primary breast cancer, 3-contralateral breast cancer, 5-relapse of breast cancer, 2-peritoneal cancer). They were subject of the further analysis.ResultsDuring the follow-up period mean age of patients after RRSO at the time of cancer diagnosis was 53.19. The mean age of patients diagnosed with primary breast cancer was 50, contralateral breast cancer – 58.67, recurrence of breast cancer - 51 and peritoneal cancer 60. The mean time periods from RRSO to the diagnosis of primary, contralateral, recurrence breast cancer were 53, 58.67 and 25,4 months respectively and of peritoneal cancer 46 months. BRCA1 c.5266dupC mutation carriers demonstrated significantly shorter time of cancer development compared to patients carrying c.181T > G and c.4035delA mutations. Peritoneal cancer was only observed in two c.181T > G BRCA1 mutation carriers.ConclusionsThe mean age of cancer diagnosis and the mean time periods from RRSO to the diagnosis of cancer are similar to those observed by other researchers. The carriers of c.181T > G and c.5266dupC BRCA1 mutation should be the subject further studies in context of breast and peritoneal cancer risk or time of cancer development after RRSO, respectively.

中文翻译：

---

BRCA1携带者在降低风险的输卵管卵巢切除术后诊断出的乳腺癌和腹膜癌的选定特征

背景 20 多年来，BRCA1/2 携带者推荐并广泛接受降低风险的输卵管卵巢切除术 (RRSO) 作为降低卵巢癌风险和提高生存率的方法。RRSO 后，仍有患乳腺癌和腹膜癌的风险。这些肿瘤的特征尚不清楚。在这项研究中，我们确定了癌症诊断时的年龄、从 RRSO 到诊断癌症的时间以及术后随访期间诊断为乳腺癌或腹膜癌的患者 BRCA1 突变类型的意义。方法材料由 195 BRCA1 携带者在 1999-2012 年间进行了 RRSO。在此期间，16名患者发生癌症（6-原发性乳腺癌，3-对侧乳腺癌，5-复发乳腺癌，2-腹膜癌）。他们是进一步分析的对象。结果在随访期间，RRSO后患者在癌症诊断时的平均年龄为53.19岁。被诊断患有原发性乳腺癌的患者的平均年龄为 50 岁，对侧乳腺癌 - 58.67 岁，乳腺癌复发 - 51 岁和腹膜癌 60 岁。从 RRSO 到诊断为原发性、对侧、复发乳腺癌的平均时间为 53 岁，分别为 58.67 和 25.4 个月，腹膜癌为 46 个月。与携带 c.181T > G 和 c.4035delA 突变的患者相比，BRCA1 c.5266dupC 突变携带者的癌症发展时间显着缩短。仅在两个 c.181T > G BRCA1 突变携带者中观察到腹膜癌。结论癌症诊断的平均年龄和从RRSO到诊断癌症的平均时间与其他研究人员观察到的相似。c.181T > G和c.5266dupC BRCA1突变的携带者应分别作为RRSO后乳腺癌和腹膜癌风险或癌症发展时间的进一步研究的主题。